New data highlight predictive patient-derived models, resistance insights, and end-to-end translational workflows to improve translational oncology confidence
SAN DIEGO, April 16, 2026 — Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced it will present new data at the AACR Annual Meeting 2026 demonstrating how integrated, patient-derived platforms can accelerate the development of complex oncology modalities, including antibody-drug conjugates (ADCs) and radiopharmaceuticals. Across 12 poster presentations, the company highlights scalable approaches to improve target selection, optimize payload design, and overcome resistance, addressing key challenges in translational oncology.
Collectively, the data underscore the need for predictive, clinically relevant models that better reflect tumor biology and treatment response. By combining patient-derived xenografts (PDX), 3D tumor organoid models, multi-omics, and imaging approaches, Crown Bioscience demonstrates how integrated workflows support more informed decision-making earlier in development, particularly as the industry advances increasingly complex therapeutic modalities.
A central focus this year is advancing ADCs through improved target validation, payload selection, and resistance modeling. New findings introduce a high-throughput organoid platform to rapidly screen payloads or ADCs and support the prediction of in vivo efficacy. The results demonstrate clear differentiation across payload classes and ADC performance in a broad panel of organoid models spanning multiple solid tumor indications, enhancing translational predictability from in vitro screening to in vivo validation, and ultimately to clinical response in patients.
Complementing this work, Crown Bioscience presents ADC-resistant tumor models spanning engineered cell lines, organoids, and PDX models established from previously treated patients. These models seek to replicate clinically relevant resistance mechanisms, including efflux-driven payload resistance and antigen loss, providing insight into treatment failure and a foundation for evaluating next-generation strategies and combination approaches designed to overcome resistance.
Further strengthening the workflow, large-scale multi-omics data validate tumor-associated antigen (TAA) expression across approximately 1,000 PDX models and matched organoid systems, providing insight to support more informed target selection and translational decision-making.
In parallel, Crown Bioscience is co-presenting a poster with Medicines Discovery Catapult on an end-to-end translational workflow for radiopharmaceutical development. This work integrates radiochemistry, imaging, and patient-derived models to evaluate the theranostic pair PSMA-617, demonstrating how the combination of in vitro and in vivo systems improves predictive accuracy and enables more confident progression of radiopharmaceutical candidates.
Together, these studies reflect a shift toward integrated, platform-based approaches that address persistent industry challenges, including limited translational predictability, incomplete understanding of resistance, and inefficiencies in candidate selection. By aligning model systems with clinically relevant biology, Crown Bioscience de-risks the path from target to patient.
Attendees are encouraged to visit Booth #3236 to learn more about these studies and speak with Crown Bioscience’s scientists to gain deeper insights into the integrated platforms and services available to advance oncology programs from discovery through to clinical development. To view all Crown Bioscience posters, click here.
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com